1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2021) Authors: Poveda, Andrés; Floquet, Anne; Ledermann, Jonathan A; Asher, Rebecca; Penson, Richard T; Oza, Amit M; Korach, Jacob; Huzarski, Tomasz; Pignata, Sandro; Friedlander, Michael; Baldoni, Alessandra; Park-Simon, Tjoung-Won; Tamura, Kenji; Sonke, Gabe S; Lisyanskaya, Alla; Kim, Jae-Hoon; Filho, Elias A... Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗